GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Evolent Health Inc (NYSE:EVH) » Definitions » Return-on-Tangible-Equity

Evolent Health (Evolent Health) Return-on-Tangible-Equity : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Evolent Health Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Evolent Health's annualized net income for the quarter that ended in Dec. 2023 was $-134 Mil. Evolent Health's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-800 Mil. Therefore, Evolent Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Evolent Health's Return-on-Tangible-Equity or its related term are showing as below:

EVH's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.215
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Evolent Health Return-on-Tangible-Equity Historical Data

The historical data trend for Evolent Health's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolent Health Return-on-Tangible-Equity Chart

Evolent Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -732.06 -1,409.90 - - -

Evolent Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evolent Health's Return-on-Tangible-Equity

For the Health Information Services subindustry, Evolent Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Evolent Health's Return-on-Tangible-Equity falls into.



Evolent Health Return-on-Tangible-Equity Calculation

Evolent Health's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-113.04/( (-306.141+-800.85 )/ 2 )
=-113.04/-553.4955
=N/A %

Evolent Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-133.644/( (-799.118+-800.85)/ 2 )
=-133.644/-799.984
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Evolent Health  (NYSE:EVH) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Evolent Health Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Evolent Health's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolent Health (Evolent Health) Business Description

Traded in Other Exchanges
Address
800 N. Glebe Road, Suite 500, Arlington, VA, USA, 22203
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. The company's two reportable segments: EHS and Clinical Solutions. The Company's EHS segment provides an integrated administrative and clinical platform for health plan administration and value-based business infrastructure and clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for specialty care management in oncology and cardiology and increasingly the musculoskeletal markets and holistic total cost of care improvement. It generates a majority of its revenue from Clinical Solutions segment.
Executives
Seth Blackley officer: President 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Daniel Joseph Mccarthy officer: PRESIDENT 800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Emily Ann Rafferty officer: Chief Operating Officer 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Toyin Ajayi director 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Mary Bridget Duffy director C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Diane Holder director 800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Richard M Jelinek director 40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035
Frank J Williams director, officer: Chief Executive Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
John Paul Johnson officer: Chief Financial Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Jonathan Weinberg officer: General Counsel 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Steve Tutewohl officer: Chief Operating Officer 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Tunde Sotunde director 800 N. GLEBE RD, SUITE 500, ARLINGTON VA 22203
Kim Keck director 30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305